Genzyme Transgenics, NeoRx deal

GZTC entered into three contracts for antibody production. The Framingham, Mass., company will develop for Bristol-Myers Squibb transgenic goats that produce BR96, a monoclonal antibody. The pharma company is running Phase II trials of a conjugate of the BR96 MAb with doxorubicin as a cancer therapy. GZTC will receive up to $2.7 million from Bristol-Myers. ...